Coeptis Reprices Equity Awards and Accelerates Option Vesting

Coeptis Therapeutics Holdings ( (COEP) ) has shared an update.

On February 11, 2026, Coeptis Therapeutics Holdings implemented a one-time option repricing and exchange program for holders of stock options under its 2022 Equity Incentive Plan, including officers and directors, allowing them to either reprice underwater options or exchange them for restricted stock. In conjunction with this program, the board approved full acceleration of option vesting, and several senior executives, including David Mehalick and other directors, surrendered options for an equal number of restricted shares and exercised remaining options in full, altering the mix of outstanding equity incentives and increasing issued restricted stock.

Separately, the company had previously fallen out of compliance with Nasdaq Listing Rules for failing to hold an annual shareholder meeting within twelve months of its December 31, 2024 fiscal year-end. On February 9, 2026, Nasdaq notified Coeptis that it had regained compliance with the annual meeting requirement for continued listing on The Nasdaq Capital Market, resolving the deficiency and closing the matter for shareholders and market participants.

More about Coeptis Therapeutics Holdings

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing therapies in the healthcare sector, with its equity-based compensation programs governed by a 2022 Equity Incentive Plan. The company is listed on The Nasdaq Capital Market, where it is subject to ongoing listing and corporate governance requirements, including the timely holding of annual shareholder meetings.

Average Trading Volume: 80,779

Technical Sentiment Signal: Hold

Current Market Cap: $70.18M

See more data about COEP stock on TipRanks’ Stock Analysis page.